Aeterna Zentaris (NASDAQ:AEZS): Aeterna Zentaris achieved a proof of concept in pre-clinical trials with their AEZS-120 oral prostate cancer vaccine, using a “tumor-challenge mouse model.” The safety toxicology and pharmacology information indicates that the profile of AEZS-120 is comparable to that of an accepted carrier strain and paves the way for Phase I trials.
Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.
Merck (NYSE:MRK): After a large study of its short term effects, the Gardasil vaccine, used to prevent cervical cancer, was found to be safe. The report was the second during the past year indicating that Gardasil causes no immediate side effects, however, there are concerns about the drug’s long-term impact. The vaccine generated $1.2 billion in revenues this past year.
Neurocrine Biosciences (NASDAQ:NBIX): Neurocrine Biosciences has begun their Phase IIb clinical trials of NBI-98854, their proprietary Vesicular Mono-Amine Transporter 2 compound to treat serious cases of Tardive Dyskinesia and underlying Schizophrenia or Schizoaffective Disorder. Topline data will be available in 2013.
Don’t Miss: AstraZeneca’s New Strategy.